Hi {{lead.First Name:default=edit me}},

Did you know that Pfizer/BioNTech relied on an in-home collected cohort of COVID-recovered individuals to benchmark their immunogenicity evaluations in preclinical and clinical vaccine trials? Working with Sanguine, researchers procured these samples prospectively and quickly during the height of the pandemic. Can we help you design a similar study and extend your therapy or vaccine evaluation trials beyond the clinic?

Immunogenicity benchmarking in COVID vaccine  trials (1).jpg

Warm Regards,

Hannah Godby
Research Consultant
Sanguine Bio | Massachusetts

Schedule a Meeting
| www.sanguinebio.com